Can patients with cholangiocarcinoma take ginsenoside Rh2? What are the effects of ginsenoside Rh2 for cholangiocarcinoma patients? Does it work well? Cholangiocarcinoma is a malignant tumor of the extrahepatic bile duct originating from the confluence of the left and right hepatic ducts to the lower end of the common bile duct. Primary cholangiocarcinoma is less common, accounting for 0.01% to 0.46% of general autopsy, 2% of tumor patient autopsy, 0.3% to 1.8% of biliary tract surgery, and 1.5 to 5 times of cholangiocarcinoma in Europe and America, and more cholangiocarcinoma than cholangiocarcinoma in Japan. The ratio of male to female is about 1.5~3.0. The age of onset is mostly 50~70 years old, but it can also be seen in young people. With the progress of natural medicinal chemistry, ginsenoside Rh2 found in ginseng has good anti-tumor activity and has been developed into a mature product for adjuvant treatment of tumors. The inhibitory activity of ginsenoside Rh2, on bile duct cancer cells, is very optimistic, and many patients have benefited from it.